NIM
NTLA icon

NEOS Investment Management’s Intellia Therapeutics NTLA Stock Holding History

NEOS Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,260
Closed -$128K – 630
2025
Q4 		$128K Sell
14,260
-460
-3% -$6.33K ﹤0.01% 650
2025
Q3 		$254K Sell
14,720
-9,333
-39% -$115K ﹤0.01% 617
2025
Q2 		$226K Sell
24,053
-2,484
-9% -$20.4K ﹤0.01% 607
2025
Q1 		$189K Sell
26,537
-101,289
-79% -$1.02M ﹤0.01% 589
2024
Q4 		$1.49M Sell
127,826
-28,388
-18% -$443K 0.04% 340
2024
Q3 		$3.21M Buy
156,214
+6,584
+4% +$152K 0.1% 189
2024
Q2 		$3.35M Buy
149,630
+74,960
+100% +$1.78M 0.14% 136
2024
Q1 		$2.05M Buy
74,670
+43,957
+143% +$1.22M 0.13% 152
2023
Q4 		$936K Buy
+30,713
New +$883K 0.09% 193

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NEOS Investment Management's NTLA Position: Q1 2026 in Review

NEOS Investment Management sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 14,260 shares — an estimated $128K sold.

NEOS Investment Management first reported a position in NTLA in Q4 2023 and held it in 9 quarters. The position peaked at $3.35M in Q2 2024. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • NEOS Investment Management reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • NEOS Investment Management sold 14,260 Intellia Therapeutics shares in Q1 2026, an estimated $128K.
  • NEOS Investment Management first reported a position in Intellia Therapeutics in Q4 2023 and held it in 9 quarters.
  • NEOS Investment Management's Intellia Therapeutics position peaked at $3.35M in Q2 2024.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on NEOS Investment Management's 13F filing for Q1 2026, filed 15 May 2026.